The biguanide drugs market is anticipated to grow at a considerable CAGR of more than 7.0% during the forecast period 2020-2026. Metformin IR (immediate release) and Metformin ER (Extended-release) are the most common biguanide in the global market. The growth in the patient pool of type 2 diabetes, increasing diagnosis rate in the emerging economies, increasing healthcare expenditure by individuals are some of the major factors which provide a significant opportunity for the companies to enter the market. As per the International Diabetes Federation (IDF), the global prevalence of diabetes in the age group of 20-79 years was 463 million in 2019. The number is expected to reach 578 million by 2030. A large share of this patient pool will be in emerging economies of Asia-Pacific, Latin America, and Middle East & Africa.
Some of the major factor active in the biguanide industry include BOEHRINGER Ingelheim International GmbH, Merck & Co., Inc., Lupin, Ltd., Bristol-Myers Squibb Co., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals, Ltd., Harman Finochem Ltd., Aarti Drugs Ltd., USV Pvt. Ltd., Mylan N.V., Apotex Corp. among others.
A Full Report of Global Biguanide Market is Available at: https://www.omrglobal.com/industry-reports/biguanide-market
Global Biguanide Market – Segmentation
By Type
• Metformin IR
• Metformin ER
• Other Biguanide
By Dosage Form
• Tablet
• Solution
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
